{
    "nct_id": "NCT06677710",
    "official_title": "A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis",
    "inclusion_criteria": "* Confirmed diagnosis of primary or non-active secondary progressive MS (SPMS) based on the 2017 revisions of the McDonald criteria.\n* Dosed with ocrelizumab within the prior 6 months.\n* Expanded Disability Status Scale (EDSS) at screening from 3.0 to 6.5 points.\n* Score of ≥2.0 on the Functional Systems (FS) scale for the pyramidal system that is due to lower extremity findings.\n* Disease duration from the onset of MS symptoms:\n\n  * Less than 15 years in patients with an EDSS at screening >5.0.\n  * Less than 10 years in patients with an EDSS at screening ≤5.0.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Relapsing remitting MS at screening or active SPMS at screening.\n* Inability to complete an MRI.\n* Contraindication for gadolinium.\n* Known presence of other neurological disorders, including but not limited to the following:\n\n  * History or known presence of CNS or spinal cord tumor (e.g., meningioma, glioma).\n  * History or known presence of infectious causes of myelopathy (e.g., syphilis, Lyme disease, Human T-lymphotropic virus 1 [HTLV-1], herpes zoster myelopathy).\n  * History or known presence of systemic autoimmune disorders potentially causing progressive neurologic disease (e.g., lupus, antiphospholipid antibody syndrome, Sjögren's syndrome, Behçet's disease).\n* Impaired cardiac function or history of clinical significant cardiac disease.\n* Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.",
    "miscellaneous_criteria": "Key"
}